Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Maria Teresa Fierro is active.

Publication


Featured researches published by Maria Teresa Fierro.


British Journal of Dermatology | 2001

The relevance of the CD4+ CD26- subset in the identification of circulating Sézary cells.

Mg Bernengo; Mauro Novelli; Pietro Quaglino; Francesco Lisa; A. De Matteis; Paola Savoia; Nazario Cappello; Maria Teresa Fierro

Background  The lack of specific markers for the phenotyping of circulating neoplastic T cells in Sézary syndrome (SS) patients makes it difficult both to ascertain the presence of clonal cells and to quantify the tumour burden in the peripheral blood. In previous reports we showed that the lack of CD26 (dipeptidyl‐aminopeptidase IV) is a characteristic feature of circulating Sézary cells (SC).


Journal of Clinical Oncology | 2006

Prognostic Factors in Primary Cutaneous B-Cell Lymphoma: The Italian Study Group for Cutaneous Lymphomas

Pier Luigi Zinzani; Pietro Quaglino; Nicola Pimpinelli; Emilio Berti; Gianandrea Baliva; Serena Rupoli; Maurizio Martelli; Mauro Alaibac; Giovanni Borroni; Sergio Chimenti; Renato Alterini; Lapo Alinari; Maria Teresa Fierro; Nazario Cappello; Alessandro Pileri; Davide Soligo; Marco Paulli; Stefano Pileri; Marco Santucci; Maria Grazia Bernengo

PURPOSE Primary cutaneous B-cell lymphomas (PCBCLs) are a distinct group of primary cutaneous lymphomas with few and conflicting data on their prognostic factors. PATIENTS AND METHODS The study group included 467 patients with PCBCL who were referred, treated, and observed in 11 Italian centers (the Italian Study Group for Cutaneous Lymphomas) during a 24-year period (1980 to 2003). All of the patients were reclassified according to the WHO-European Organisation for Research and Treatment of Cancer (EORTC) classification. RESULTS Follicle center lymphoma (FCL) accounted for 56.7% of occurrences, followed by marginal-zone B-cell lymphoma (MZL; 31.4%); diffuse large B-cell lymphoma (DLBCL), leg type, was reported in 10.9% of patients. Radiotherapy was the first-line treatment in 52.5% of patients and chemotherapy was the first-line treatment in 24.8% of patients. The complete response rate was 91.9% and the relapse rate was 46.7%. The 5- and 10-year overall survival (OS) rates were 94% and 85%, respectively. Compared with FCL/MZL, DLBCL, leg type, was characterized by statistically significant lower complete response rates, higher incidence of multiple cutaneous relapses and extracutaneous spreading, shorter time to progression, and shorter OS rates. The only variable with independent prognostic significance on the OS was the clinicopathologic diagnosis according to the WHO-EORTC classification (DLBCL, leg-type, showed a significantly worse prognosis v FCL and MZL; P < .001), whereas the only variable with independent prognostic significance on disease-free survival was the presence of a single cutaneous lesion (P = .001). CONCLUSION Our study identifies a possible PCBCL subclassification and the extent of cutaneous involvement as the two most relevant prognostic factors in PCBCL. These data can be considered reasonably as the clinical background for an appropriate management strategy.


Annals of Oncology | 1998

Prognostic factors in Sézary syndrome: A multivariate analysis of clinical, haematological and immunological features

Mg Bernengo; Pietro Quaglino; Mauro Novelli; Nazario Cappello; Gc Doveil; Francesco Lisa; A. De Matteis; Maria Teresa Fierro; Appino

BACKGROUND Sézary syndrome (SS) prognostic factors are not well defined because of the rarity of this disease. The specific goal of this prospective study was to assess by multivariate analysis the predictive value with respect to survival of a series of clinical, haematological and immunological parameters taken at SS diagnosis. PATIENTS AND METHODS A cohort of 62 SS patients diagnosed and followed since 1975 was examined, and 51 were included in the multivariate analysis model. RESULTS The median survival time was 31 months (range: 1 month-15.7+ years), and the five-year survival rate 33.5%. The following variables were found by univariate analysis to be associated with a poor prognosis at the time of SS diagnosis: previous history of mycosis fungoides (P = 0.013), high number of circulating leukocytes (P = 0.001), Sézary cells (SC) (P < 0.001) and CD4+ cells (P < 0.001), presence of large circulating SC (P < 0.001), above normal range LDH serum levels (P = 0.015), presence of PAS-positive inclusions in the cytoplasm of circulating SC (P < 0.001), high CD4/CD8 ratio (P = 0.004) and a CD7 negative circulating SC phenotype (P < 0.001). Among them, the stepwise multivariate analysis selected as adverse independent prognostic factors: PAS-positive cytoplasmic inclusions (P = 0.001), CD7 negative phenotype (P = 0.018) and presence of large circulating SC (P = 0.045). CONCLUSIONS Two low-/high-risk groups have been singled out on the basis of the risk index. Patients with no or one adverse prognostic feature(s) (risk index < or = 1; n = 31) share a slow disease course and a relatively favorable prognosis (five-year survival: 58%); on the other hand, patients with 2 or 3 adverse prognostic feature (risk index > 1; n = 20) are characterized by an aggressive disease course not modifiable by traditional therapies (five-year survival: 5%).


British Journal of Dermatology | 2005

T-cell receptor gamma gene rearrangement by multiplex polymerase chain reaction/heteroduplex analysis in patients with cutaneous T-cell lymphoma (mycosis fungoides/Sézary syndrome) and benign inflammatory disease: correlation with clinical, histological and immunophenotypical findings.

Renata Ponti; Pietro Quaglino; Mauro Novelli; Maria Teresa Fierro; Alessandra Comessatti; Anna Peroni; Lisa Bonello; Maria Grazia Bernengo

Background  A dominant T‐cell clone can be detected by polymerase chain reaction (PCR) in 40–90% of cutaneous samples from patients with cutaneous T‐cell lymphoma (CTCL).


Annals of Oncology | 2010

Vitiligo is an independent favourable prognostic factor in stage III and IV metastatic melanoma patients: results from a single-institution hospital-based observational cohort study

Pietro Quaglino; F. Marenco; Simona Osella-Abate; Nazario Cappello; M. Ortoncelli; B. Salomone; Maria Teresa Fierro; Paola Savoia; Maria Grazia Bernengo

BACKGROUND The clinical features and the prognostic relevance of vitiligo lesions in melanoma patients are still controversial. This prospective observational study was designed to characterise the clinical features of melanoma-associated vitiligo, to analyse the association with other autoimmune manifestations and to ascertain whether the development of vitiligo lesions carries a prognostic relevance on the clinical course of melanoma. MATERIALS AND METHODS A total of 2954 consecutive patients have been included; multivariate analyses of distant metastasis-free survival (DMFS) and overall survival (OS) were carried out to ascertain the independent prognostic role of vitiligo as a time-dependent covariate. RESULTS Vitiligo was demonstrated in 83 of 2954 melanoma patients (2.8%). A significantly higher percentage of autoimmune diseases was demonstrated in vitiligo patients (7 of 83) with respect to patients without vitiligo (80 of 2871) (P = 0.004). Multivariate analyses selected the time-dependent covariate vitiligo as the favourable independent prognostic variable associated to a longer DMFS in stage III and a higher OS in both stage III and stage IV. CONCLUSION Melanoma-associated vitiligo should be considered as a distinct clinical entity, separate from vitiligo vulgaris, and identifies a subgroup of patients characterised by a high prevalence of immune-mediated diseases and by a favourable prognosis.


British Journal of Dermatology | 1997

CD56-positive cutaneous lymphoma: a poorly recognized entity in the spectrum of primary cutaneous disease.

Paola Savoia; Maria Teresa Fierro; Mauro Novelli; Pietro Quaglino; A. Verrone; M. Geuna; Maria Grazia Bernengo

CD56‐positive (CD56+) lymphomas, characterized by the expression of the neural cell adhesion molecule on pathological lymphocytes, share a frequent extranodal involvement and a generally aggressive course. Five CD3‐ CD56+ lymphoma patients presenting with nodular lesions were identified among 180 immunophenotyped cutaneous lymphomas. All the patients were men, with ages ranging from 55 to 78 years. After staging, two patients were diagnosed as having primary cutaneous lymphomas: the remaining three had the secondary cutaneous type. The clinical course was aggressive and four patients died within 8 months from diagnosis. The remaining patient is still alive after a 17‐month follow‐up. The histological diagnosis was immunoblastic lymphoma in two patients, and medium and large cell pleomorphic lymphoma in three. The angiocentric infiltrate was located mainly in the dermis: azurophilic granules were present in three of the five patients. Immunogenotypic analyses suggested the natural killer cell origin of these neoplasias: all cases exhibited a CD56+ CD3‐ CD5‐ T‐cell receptor (TCR) silent phenotype, and Southern blot analysis showed a germline configuration of the TCR β‐chain gene.


Leukemia & Lymphoma | 1998

SYSTEMIC POLYCHEMOTHERAPY IN THE TREATMENT OF PRIMARY CUTANEOUS LYMPHOMAS : A CLINICAL FOLLOW-UP STUDY OF 81 PATIENTS TREATED WITH COP OR CHOP

Maria Teresa Fierro; Pietro Quaglino; Paola Savoia; A. Verrone; Maria Grazia Bernengo

The efficacy of systemic polychemotherapy in the treatment of primary cutaneous B-cell lymphomas (CBCL) or T-cell lymphomas (CTCL) is still controversial. A series of 81 patients (46 primary CBCL and 35 CTCL) were treated with COP or CHOP regimens. In primary CBCL, the overall objective response rate (RR) was 98%, with an 89% CR rate and a 33% relapse-rate. Five-year disease-free survival was 70%, 5-year survival 97%. Patients with leg or widespread lesions showed a higher relapse-rate (55% vs 26%) than those with trunk or head lesions. The overall objective RR was 40% in CTCL patients, with a 23% CR rate; median response duration was 5.7 months, median survival 19 months. The results confirm both the good prognosis of primary CBCL and the efficacy of polychemotherapy. CHOP regimen is to be preferred to COP in as much as it reduces relapse rates. Conversely, there are no indications for the use of COP/CHOP regimens as first-line chemotherapy in CTCL patients.


British Journal of Haematology | 1990

Interleukin 2 does not promote the in vitro and in vivo proliferation and growth of human acute leukaemia cells of myeloid and lymphoid origin

R. Foa; P. Caretto; Maria Teresa Fierro; Margherita Bonferroni; S. Cardona; Anna Guarini; Patrizia Lista; Luigi Pegoraro; F. Mandelli; Guido Forni; F. Gavosto

The effect of recombinant interleukin 2 (IL2) on the in vitro and in vivo proliferation and growth of human acute leukaemia cells of both myeloid and lymphoid origin was investigated. In none of the 25 primary samples tested could a continuously in vitro growing cell line be obtained by adding IL2 to the culture medium. Although IL2 induced a proliferative signal in three of the 31 acute leukaemias analysed, the overall 3H‐thymidine uptake of the neoplastic cells was significantly reduced (P<0.05) in the presence of IL2. The unlikelihood of an important proliferative signal triggered by IL2 was confirmed in a semisolid clonogenic assay, which failed to document an increased colony growth in the 26 samples studied. Furthermore, using a colorimetric assay as a test for cell proliferation and survival, in seven of the 11 fresh acute leukaemia samples tested a 22–40% reduction in viability was observed in the presence of IL2, while in the remaining four, IL2 was ineffective. In order to investigate the effect of IL2 in an in vivo setting, an experimental model in heavily immunosuppressed nu/nu mice was established. In no case did IL2 promote the in vivo proliferation and growth of human myeloid and lymphoid acute leukaemia cells injected in the mice. On the contrary, with seven of the eight leukaemic cell lines which gave rise spontaneously to leukaemic masses, this could be prevented when the mice received locally 300 U of IL2 three times daily for 90 d. IL2 also blocked the growth in vivo of three fresh acute leukaemia samples (two myeloid and one lymphoid). Co‐culture experiments using leukaemic cell lines and increasing numbers of normal lymphocytes suggest that the inhibitory effect of IL2 is probably exerted via an indirect mechanism. These findings, coupled to the well‐documented ability of IL2 to generate lymphokine activated killer cells cytolytic against leukaemic blasts, further point to the potential role of immunotherapy with IL2 in the management of patients with haematological malignancies.


British Journal of Haematology | 1984

Discrepancy between phenotypic and functional features of natural killer T-lymphocytes in B-cell chronic lymphocytic leukaemia

R. Foa; Francesco Lauria; Paolo Lusso; M. C. Giubellino; Maria Teresa Fierro; M. L. Ferrando; Donatella Raspadori; Lina Matera

Summary. The phenotypic expression and functional capacity of natural killer (NK) T‐lymphocytes (E+, OKT3 +) were analysed in a series of untreated patients with B‐cell chronic lymphocytic leukaemia (B‐CLL).


British Journal of Haematology | 1983

T-cell functional abnormality in B-chronic lymphocytic leukaemia: Evidence of a defect of the T-helper subset

Francesco Lauria; R. Foa; V. Mantovani; Maria Teresa Fierro; D. Catovsky; Sante Tura

Summary. The helper and suppressor capacity of T, Tμ (T nonγ) and Tγ cells was assessed in a group of patients with B‐cell chronic lymphocytic leukaemia (B‐CLL) in a pokeweed mitogen (PWM) stimulated system. The enriched T‐cells (E‐rosette positive) from all B‐CLL cases showed a reduced capacity to induce the differentiation of normal B‐lymphocytes compared with normal T‐cells (P<0·005). After enrichment of the Tμ cells, the helper/inducer capacity was still significantly depressed compared with the same fraction from normal controls (P<0·01). On the other hand, enriched Tγ cells from B‐CLL were effective in suppressing the differentiation of normal B‐lymphocytes to a similar degree as normal Tγ cells. These findings are indicative of a deficient T‐cell helper function in B‐CLL, which appears to be unrelated to the clinical stage of the disease. The fractionation experiments suggest that this functional impairment is not only due to the abnormal T‐cell subset distribution seen in the majority of cases, but point to a possible intrinsic defect within the Tμ cell population.

Collaboration


Dive into the Maria Teresa Fierro's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

R. Foa

Sapienza University of Rome

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Paolo Lusso

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge